These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 9779989)

  • 21. Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis.
    Scott AN; Hetheridge C; Reynolds AR; Nayak V; Hodivala-Dilke K; Mellor H
    Angiogenesis; 2008; 11(4):337-46. PubMed ID: 18758974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
    Morgan MA; Wegner J; Aydilek E; Ganser A; Reuter CW
    Leukemia; 2003 Aug; 17(8):1508-20. PubMed ID: 12886237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase.
    Wherlock M; Gampel A; Futter C; Mellor H
    J Cell Sci; 2004 Jul; 117(Pt 15):3221-31. PubMed ID: 15226397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB.
    Lebowitz PF; Casey PJ; Prendergast GC; Thissen JA
    J Biol Chem; 1997 Jun; 272(25):15591-4. PubMed ID: 9188444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
    Crespo NC; Delarue F; Ohkanda J; Carrico D; Hamilton AD; Sebti SM
    Cell Death Differ; 2002 Jul; 9(7):702-9. PubMed ID: 12058275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
    Delarue FL; Adnane J; Joshi B; Blaskovich MA; Wang DA; Hawker J; Bizouarn F; Ohkanda J; Zhu K; Hamilton AD; Chellappan S; Sebti SM
    Oncogene; 2007 Feb; 26(5):633-40. PubMed ID: 16909123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells.
    Kim HS; Kim JW; Gang J; Wen J; Koh SS; Koh JS; Chung HH; Song SY
    Toxicol Appl Pharmacol; 2006 Sep; 215(3):317-29. PubMed ID: 16712893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
    Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
    Lerner EC; Hamilton AD; Sebti SM
    Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment.
    Lebowitz PF; Sakamuro D; Prendergast GC
    Cancer Res; 1997 Feb; 57(4):708-13. PubMed ID: 9044849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
    Zeng PY; Rane N; Du W; Chintapalli J; Prendergast GC
    Oncogene; 2003 Feb; 22(8):1124-34. PubMed ID: 12606940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rho GTPases: promising cellular targets for novel anticancer drugs.
    Fritz G; Kaina B
    Curr Cancer Drug Targets; 2006 Feb; 6(1):1-14. PubMed ID: 16475973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
    Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
    Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
    Cox AD
    Drugs; 2001; 61(6):723-32. PubMed ID: 11398905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
    Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
    J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells.
    Pan J; She M; Xu ZX; Sun L; Yeung SC
    Cancer Res; 2005 May; 65(9):3671-81. PubMed ID: 15867362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cell-based radioligand binding assay for farnesyl: protein transferase inhibitors.
    Lobell RB; Davide JP; Kohl NE; Burns HD; Eng WS; Gibson RE
    J Biomol Screen; 2003 Aug; 8(4):430-8. PubMed ID: 14567795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
    Bernhard EJ; Kao G; Cox AD; Sebti SM; Hamilton AD; Muschel RJ; McKenna WG
    Cancer Res; 1996 Apr; 56(8):1727-30. PubMed ID: 8620483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors.
    Liu Ax; Du W; Liu JP; Jessell TM; Prendergast GC
    Mol Cell Biol; 2000 Aug; 20(16):6105-13. PubMed ID: 10913192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.